Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS 2Q Revenues up 16% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

BMS 2Q Revenues up 16%

Top sellers Revlimid, Eliquis and Opdivo drive growth while established brands were down 64%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol Myers Squibb
2Q Revenues: $11.7 billion (+16%)
2Q Earnings: $1.1 billion (loss of $80 million 2Q20)
Comments: Revlimid sales were $3.2 billion in the quarter, up 11%. Eliquis sales were $2.8 billion, up 29%. Opdivo sales were $1.9 billion, up 16%. Orencia sales were $814 million, up 9%. Pomalyst /Imnovid sales were up 15% to $854 million. Sprycel sales were $541 million, up 6%. Yervoy sales were $510 million, up 38%. Abraxane sales were down 4% to $296 million, and Empliciti sales were down 11% to $86 million. Reblozyl sales reached $128 million in the quarter. Established Brands: Vidaza sales were down 64% to $45 million. Baraclude sales were down 10% to $109 million. Other brands revenue was $319 million, down 4% in the quarter. R&D expenses increased 30% to $3.3 billion in the quarter primarily due to higher license and asset acquisition charges and an in-process research and development (IPR&D) impairment charge.

Read Contract Pharma’s Top Companies Report on BMS.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters